Replies to post #331395 on Anavex Life Sciences Corp (AVXL)

[raja48185]

Thanks for the detailed post.

[Kb1123]

Great to hear from you! Hope all is well!

[toemind]

Thanks for the very nice summation.

[HMB2010]

Thank you

[xodcode]

Thanks Mayo.

Reinforces the notion of AVXL's highly positive converging indicators. TGD is very busy.

[LBSR TO DA MOON]

Alzheimer’s study readout will be available by this time in 2022.

It sure would be awesome if this becomes the first timeline to actually be hit on time!

- Value creation: Rett syndrome will be first to market. Additionally, Alzheimer’s study readout will be available by this time in 2022.

[Cbdpotential]

Thank you ! Looking great imo
$AVXL

[frrol]

Great summary for those who missed it

[Investor2014]

Thanks for the summary.

I noticed Charles Duncan introducing Anavex Pharmaceuticals, a slipup rather than a slip of the tongue I am sure.

[RedShoulder]

Thanks Mayo, as usual for you, a very detailed report.

[tredenwater2]

Thank you Mayo, great job.

[Boopka]

Mayo, thank you for taking the time to post.

The only thing that raised an eyebrow for me was Missling stating the "Ultra Rare Disease Trial" that they were preparing. Wonder what the criteria was for Anavex choosing a particular disease and why an ultra rare one at that. Missling himself earlier stated that they were looking at multiple indications and that they wanted to make sure they picked the right one. From an investors standpoint an ultra rare disease limits the number of candidates but it does maximize sales per patient. I am curious as to how it will wash out and how long it will take.